How to Stop Cyber Attacks: Let Workers Smoke Pot

How to Stop Cyber Attacks: Let Workers Smoke Pot

An Initiative To Legalize Marijuana In California To Appear On Nov. Ballot
Justin Sullivan/Getty Images
By Jackie Leo

What’s true for the government is true for business. FBI Director James Comey thinks you can’t hire top tech talent with a ban on weed. It all started in the Reagan administration, which imposed a no-hire policy for applicants who toked up within the past three years. Good luck with that.

In 2014, Comey raised the issue during a speech: “A lot of the nation’s top computer programmers and hacking gurus are also fond of marijuana. I have to hire a great workforce to compete with those cyber criminals and some of those kids want to smoke weed on the way to the interview.”

That’s not the only reason the government can’t hire competent programmers and white hat hackers.  They come at a high price, there’s a shortage, and they hate red tape and bureaucratic annoyances.  For some lawmakers, though, it’s easier to get lost in the weed than try to reform the federal hiring process.  That’s why Gerry Connolly (D-VA) and Earl Blumenauer (D-OR) have two proposals in the House requiring info from the intelligence director on how classifying pot as Schedule 1 narcotic crimps the feds recruiting efforts.  

Chart of the Day: Boosting Corporate Tax Revenues

GraphicStock
By The Fiscal Times Staff

The leading candidates for the Democratic presidential nomination have all proposed increasing taxes on corporations, including raising income tax rates to levels ranging from 25% to 35%, up from the current 21% imposed by the Republican tax cuts in 2017. With Bernie Sanders leading the way at $3.9 trillion, here’s how much revenue the higher proposed corporate taxes, along with additional proposed surtaxes and reduced tax breaks, would generate over a decade, according to calculations by the right-leaning Tax Foundation, highlighted Wednesday by Bloomberg News.

Chart of the Day: Discretionary Spending Droops

By The Fiscal Times Staff

The federal government’s total non-defense discretionary spending – which covers everything from education and national parks to veterans’ medical care and low-income housing assistance – equals 3.2% of GDP in 2020, near historic lows going back to 1962, according to an analysis this week from the Center on Budget and Policy Priorities.

Chart of the Week: Trump Adds $4.7 Trillion in Debt

By The Fiscal Times Staff

The Committee for a Responsible Federal Budget estimated this week that President Trump has now signed legislation that will add a total of $4.7 trillion to the national debt between 2017 and 2029. Tax cuts and spending increases account for similar portions of the projected increase, though if the individual tax cuts in the 2017 Republican overhaul are extended beyond their current expiration date at the end of 2025, they would add another $1 trillion in debt through 2029.

Chart of the Day: The Long Decline in Interest Rates

Wall Street slips, Dow posts biggest weekly loss of 2013
Reuters
By The Fiscal Times Staff

Are interest rates destined to move higher, increasing the cost of private and public debt? While many experts believe that higher rates are all but inevitable, historian Paul Schmelzing argues that today’s low-interest environment is consistent with a long-term trend stretching back 600 years.

The chart “shows a clear historical downtrend, with rates falling about 1% every 60 years to near zero today,” says Bloomberg’s Aaron Brown. “Rates do tend to revert to a mean, but that mean seems to be declining.”

Chart of the Day: Drug Price Plans Compared

By The Fiscal Times Staff

Lawmakers are considering three separate bills that are intended to reduce the cost of prescription drugs. Here’s an overview of the proposals, from a series of charts produced by the Kaiser Family Foundation this week. An interesting detail highlighted in another chart: 88% of voters – including 92% of Democrats and 85% of Republicans – want to give the government the power to negotiate prices with drug companies.